HIV prevention pill study for people who use drugs
Part of Infections clinical trials.
This study looks at how well a daily HIV prevention pill (F/TAF) works for people who use drugs. It also includes interviews with healthcare providers and peer navigators to understand how to better support patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You can communicate in English.
- You have tested negative for HIV.
- You have used injection drugs in the last 6 months or other drugs in the last 12 months.
- You can provide a contact person for follow-up.
- You are not pregnant, not currently incarcerated, and do not have significant cognitive or developmental impairments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a program to help men who use stimulants and are at risk for HIV reduce drug use and prevent HIV infection. Participants may get access to PrEP, a daily pill that prevents HIV, and support to lower their risk.
This study helps young people who are at risk for HIV get on PrEP—a daily pill or shot that prevents HIV. It tests different ways to help you start and stay on PrEP, with care available at clinics or in your community.
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
This trial tests a new way to take HIV prevention medicine (PrEP) only around the time you have sex, using a pill called TAF/FTC. It aims to see if this 'on-demand' method is effective, safe, and acceptable, and could offer a more flexible option than taking a pill every day.
This study tests different ways to help people who inject drugs stay on PrEP, a daily pill that prevents HIV. It's for people who are HIV-negative and have recently injected drugs.
This study tests how to better support HIV prevention for people who inject drugs and are newly starting PrEP (medicine to prevent HIV). It focuses on people taking medication for opioid use disorder and who have mild thinking and memory problems, to help them stay safe and adhere to prevention.
Hear when a new PrEP Adherence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.